▼

Monday, June 22, 2026

How to Choose the best Intraocular Lens Implant (IOL) for Your Cataract Surgery in 2026

 

Eight Premium Lenses, One Honest Chart

Cataract Surgery  ·  Premium Lens Guide 2026

Eight Premium Lenses, One Honest Chart: How to Choose a Cataract Lens in 2026

A cataract surgeon lays every major premium intraocular lens side by side, from the familiar PanOptix to the brand new enVista Envy, using the real trial numbers instead of the brochure language.

By Sandra Lora Cremers, MD, FACS  ·  Visionary Eye Doctors  ·  EyeDoc2020

Every week a patient sits across from me and asks the same fair question. If I am going to replace the lens inside my eye one time, for the rest of my life, which lens should it be. The honest answer is that there is no single best lens. There is only the best lens for your eyes, your daily tasks, and your tolerance for trade offs.

The brochures rarely say that out loud. They show a smiling person reading a menu at sunset and imply that one implant does everything for everyone. So I built the chart I wish every patient could see before they sign a consent form. It pulls together the published trial data for the eight lenses I am asked about most often in 2025 and 2026, and it lays the strengths and the costs next to each other in plain language.

START HEREThe five kinds of lens you are actually choosing between

Marketing names multiply every year, but almost every premium lens falls into one of a few honest categories. Understanding the category tells you most of what you need to know before you ever look at a single percentage.

Trifocal lenses split incoming light into distance, intermediate, and near focal points. The Clareon PanOptix is the established example. They give the widest glasses free range, and the cost of splitting light is that some patients see rings or halos around lights at night.

Hybrid lenses blend a trifocal pattern with a continuous range of focus to soften the gaps between focal points. The TECNIS Synergy and the newer TECNIS Odyssey live here. They aim for a seamless range from across the room to the phone in your hand, and like trifocals they ask you to accept some nighttime halos in exchange.

Nondiffractive extended depth of focus lenses, such as the AcrySof IQ Vivity, stretch a single zone of focus rather than splitting light into separate points. They protect night vision and contrast almost like a standard lens, and the cost is that fine near work usually still needs readers.

Purely refractive extended depth of focus lenses, including the TECNIS PureSee and the new enVista Envy from Bausch and Lomb, reach the same goal without any diffractive rings on the optic at all. Their selling point is a halo and glare profile close to a standard monofocal while still adding useful intermediate and functional near vision.

Adjustable and premium monofocal lenses round out the field. The Light Adjustable Lens from RxSight is a monofocal whose power you tune with light treatments after surgery, which lets us chase a personalized target. The enVista MX60E is a glistening free monofocal that delivers superb sharp distance vision and crisp contrast when a single clear focus is the goal.

THE CHARTEvery lens, side by side

Here is the full comparison. The acuity columns report how patients did without glasses in the published trials. The columns on the right are where the real decision lives, because they describe night vision, contrast, freedom from glasses, and how often patients end up unhappy enough to consider an exchange. Scroll the table sideways to see all of it.

IOL Comparison Chart, Premium Intraocular Lenses, 2025 to 2026 Uncorrected visual acuity reported as percent achieving the listed line, or as mean logMAR where trials reported it that way.
Lens Company Type and design Material Distance, percent at 20/20 Intermediate, percent at 20/25 Near, percent at 20/25 Halos and glare Contrast sensitivity Spectacle independence Explant or dissatisfaction risk Key refs
Clareon PanOptix (CNWT)Trifocal Alcon Trifocal, diffractive Hydrophobic acrylic (Clareon) ~73% ~73% ~50% Moderate. Halos reported but well tolerated; 100% report no hazy vision Mildly reduced at high spatial frequencies versus monofocal ~85 to 89% never or rarely need glasses at any distance Low (~2.4% exchange rate across premium lenses); glistenings eliminated with Clareon material 1, 3, 8
TECNIS SynergyHybrid Johnson & Johnson Vision Trifocal and EDOF hybrid, diffractive Hydrophobic acrylic ~67% ~64% (20/20) ~47% (20/20) Higher. Halos the most common complaint; statistically more halos than PanOptix and Symfony Comparable to monofocal in meta analyses ~92 to 96% never need glasses at any distance Low; halos are the leading cause of dissatisfaction when it occurs 5, 6
TECNIS OdysseyHybrid Johnson & Johnson Vision Trifocal and EDOF hybrid, next generation diffractive Hydrophobic acrylic Excellent (mean -0.05 logMAR binocular) Excellent (mean 0.02 logMAR at 66 cm) Good (mean 0.04 logMAR at 40 cm) Moderate. 32% report halos always, but 0% extremely bothered Superior mesopic contrast versus Synergy and PanOptix ~80% need glasses not at all or a little; 89% spectacle independent Early data; photic phenomena profile comparable to PanOptix 7, 8, 9
AcrySof IQ VivityEDOF Alcon EDOF, nondiffractive, wavefront shaping Hydrophobic acrylic Excellent (mean 0.01 logMAR) Excellent, 88% achieve 20/25 Limited, mean about 20/32 at 40 cm Low. 85% report none or just a little glare or halo; significantly less than trifocals Preserved; comparable to monofocal ~33% never need glasses for all tasks; ~65% independent for distance and intermediate Low; favorable dysphotopsia profile reduces dissatisfaction 10, 11, 12, 13, 14
TECNIS PureSeeEDOF Johnson & Johnson Vision EDOF, purely refractive Hydrophobic acrylic Excellent (mean -0.06 logMAR binocular) Excellent, 94% spectacle free at intermediate Functional, mean 0.20 logMAR; 66% spectacle free near Very low. Noninferior to monofocal for halos and glare; ~92% not bothered Comparable to monofocal within normal age limits 100% distance, 94% intermediate, 66% near Very low; monofocal like dysphotopsia profile 15, 16, 17
Light Adjustable Lens (LAL 2.0)Adjustable RxSight Monofocal, adjustable after surgery Silicone, UV responsive ~89 to 93% achieve 20/20 binocularly (blended vision) Good with a blended vision plan; not inherently multifocal 85% achieve J1 or better with blended vision Very low. Monofocal optic; no diffractive rings Excellent; equal to a monofocal Depends on the plan. Blended vision gives high near and distance independence; matched eyes need readers Very low explant rate; requires 3 light lock in treatments and UV protective glasses for about 2 weeks 19, 20, 21, 22
enVista MX60EMonofocal Bausch + Lomb Monofocal Hydrophobic acrylic, glistening free Excellent (mean 20/18 corrected distance) Limited, mean 20/31 corrected intermediate Limited, mean 20/30 corrected near Very low. 7% moderate or severe glare; 11% moderate or severe halos Excellent; best among all categories Very low. About 96% need glasses for intermediate and near Very low; stable platform; glistening free material 23
enVista Envy (MX60EF)Full range Bausch + Lomb Full visual range, nondiffractive EDOF Hydrophobic acrylic, glistening free Noninferior to monofocal Superior, about 20/25 plateau from -1.5 to -2.5 D Superior, about 20/25 at 40 cm Low. Contrast difference versus monofocal below the minimum detectable difference Comparable to monofocal, within 0.11 logCS ~92% satisfied with near vision; ~92% spectacle free for near tasks Early data from the FDA pivotal trial; glistening free material 24, 25

Key reference numbers map to the numbered list at the foot of this article. On a phone, swipe the table left and right to see all columns; the lens name stays fixed.

HOW TO READ ITThe trade is always the same three way pull

If you study the chart long enough, one pattern appears in every row. Premium lenses are pulling against three goals at once, and no lens wins all three. The goals are a full glasses free range, clean night vision with strong contrast, and a low chance of regret. Push hard toward one and you usually give a little on another.

The trifocal and hybrid lenses, PanOptix, Synergy, and Odyssey, push hardest toward a full range. That is why their spectacle independence numbers are the highest in the chart, and also why halos at night appear more often in their rows. For most patients those halos settle and become a minor footnote, but a person who drives for a living at night should hear about them plainly.

The extended depth of focus lenses, Vivity, PureSee, and the enVista Envy, push toward clean night vision and a low chance of regret. Their halo and contrast rows read almost like a standard lens. The cost shows up in the near column, where fine print at reading distance is functional rather than effortless, so a pair of readers may still live in your bag.

The Light Adjustable Lens and the enVista MX60E push toward precision and a low chance of regret in a different way. The MX60E gives the sharpest single focus and the best contrast in the chart, and asks you to wear glasses for everything closer than the horizon. The Light Adjustable Lens lets us fine tune your result after the eye has healed, which is uniquely powerful for eyes that have had previous surgery, as long as you are willing to return for the light treatments.

There is no lens that gives a full glasses free range, perfect night vision, and zero adaptation all at once. Anyone who tells you otherwise is selling, not advising. The skill is matching the trade to your life.

FOR PATIENTSWho actually needs glasses after surgery

This is the question patients really mean when they ask which lens is best. Here is the same evidence translated into the only currency that matters at the kitchen table, which is how often you reach for glasses.

Who needs glasses after surgery A plain language summary of the spectacle independence data above.
Lens Distance Intermediate, computer and dashboard Near, phone and fine print Bottom line on glasses
Clareon PanOptixExcellentStrongStrong~85 to 89% never or rarely need glasses at any distance
TECNIS SynergyExcellentStrongStrongest near range in the chart~92 to 96% never need glasses at any distance
TECNIS OdysseyExcellentStrongGood~80% need glasses not at all or a little; 89% spectacle independent
AcrySof IQ VivityExcellentExcellentReaders for fine print~33% never need glasses for all tasks; ~65% free for distance and intermediate
TECNIS PureSeeExcellentExcellent, 94% freeFunctional, readers for small print100% distance, 94% intermediate, 66% near
Light Adjustable LensTunable to targetDepends on planHigh with blended visionBlended vision gives strong near and distance freedom; matched eyes need readers
enVista MX60EExcellentGlasses neededGlasses neededDistance only; about 96% need glasses for intermediate and near
enVista EnvyExcellentSuperiorSuperior for an EDOF~92% spectacle free for near tasks; designed for a continuous range

THE QUICK READHow I describe each lens in clinic

Clareon PanOptix trifocal, Alcon

The most proven full range lens in the United States. If your priority is to spend as little time as possible in glasses across all distances, and you accept that lights may have rings around them for a while, this is the workhorse. The Clareon material also ended the old problem of glistenings.

TECNIS Synergy hybrid, Johnson and Johnson Vision

The strongest continuous near to distance range here, which is why up to 96% of patients never reach for glasses. The trade is the most halo, so I steer night drivers and very particular personalities toward something else.

TECNIS Odyssey hybrid, Johnson and Johnson Vision

The next generation that aims to keep the wide range while cleaning up the night vision. Early data is encouraging, with better mesopic contrast than Synergy and PanOptix and no patients extremely bothered by halos.

AcrySof IQ Vivity nondiffractive EDOF, Alcon

My choice for the patient who wants more than a monofocal but will not gamble on night vision, including many glaucoma and macular patients. Excellent distance and intermediate, monofocal like contrast, and readers for fine print.

TECNIS PureSee purely refractive EDOF, Johnson and Johnson Vision

A refractive design that delivers a halo profile close to a standard lens with a genuinely useful intermediate range and functional near. A strong option for someone who fears glare more than they mind occasional readers.

Light Adjustable Lens adjustable monofocal, RxSight

The most personalized result available, because we tune the power with light after the eye heals. Uniquely valuable after previous refractive or retinal surgery. It asks for commitment to the lock in visits and UV protection for about two weeks.

enVista MX60E monofocal, Bausch and Lomb

When a single crisp focus is the goal, this glistening free monofocal gives the sharpest distance and the best contrast in the chart. Plan on glasses for intermediate and near.

enVista Envy full range nondiffractive EDOF, Bausch and Lomb

The newest entry, and an interesting one. The pivotal trial showed a continuous range of about four diopters with a contrast profile that was statistically indistinguishable from a monofocal, plus very high satisfaction with near vision. Early data, but a genuine attempt to give range without the night vision penalty.

MY BOTTOM LINEWhat I tell my own family

Choose the trade you can live with, not the lens with the best advertisement. If a full glasses free life matters most and your eyes are otherwise healthy, a trifocal or hybrid earns its place. If you value clean night vision and a low chance of regret, an extended depth of focus lens is the smarter bet and you keep a pair of readers nearby. If your eye has a complicated history, the Light Adjustable Lens lets us correct course after the fact. The right answer comes from your eyes and your day, measured carefully and discussed honestly, which is exactly what a good preoperative evaluation is for.

This article is for education and is not medical advice. Outcomes vary with each eye, and lens selection should be made with your own surgeon after a complete examination. I have no financial relationship that determines the recommendations above. The data summarized here reflects published peer reviewed trials current to early 2026.

References

  1. Kohnen T, Kaiser KP, Biller M, et al. Visual performance after implantation of a new trifocal IOL with an advanced hydrophobic acrylic biomaterial. J Cataract Refract Surg. 2025. doi:10.1097/j.jcrs.0000000000001688
  2. Moshirfar M, Stoakes IM, Theis JS, et al. Assessing visual outcomes: a comparative study of US FDA premarket approval data for multifocal and EDOF lens implants in cataract surgery. J Clin Med. 2023;12(13):4365. doi:10.3390/jcm12134365
  3. Mendicute J, Lauzirika G, Illarramendi I, Martinez-Soroa I. Visual, refractive, functional, and patient satisfaction outcomes after implantation of a new trifocal diffractive intraocular lens. Clin Ophthalmol. 2024;18:2785-2795. doi:10.2147/OPTH.S480311
  4. Susanna BN, Snider MJE, Hammoud B, Ferguson TJ, Randleman JB. Prevalence of presbyopia correcting intraocular lens satisfaction, dissatisfaction, and intolerance. J Refract Surg. 2025;41(11):e1223-e1232. doi:10.3928/1081597X-20250915-03
  5. De Rojas JO, Sandoval HP, Potvin R, Solomon KD. Visual outcomes, quality of vision, patient satisfaction and spectacle independence after bilateral implantation of the Synergy intraocular lens. Clin Ophthalmol. 2023;17:2277-2285. doi:10.2147/OPTH.S421185
  6. Ferreira TB, Ribeiro FJ, Silva D, et al. Comparison of refractive and visual outcomes of 3 presbyopia correcting intraocular lenses. J Cataract Refract Surg. 2022;48(3):280-287. doi:10.1097/j.jcrs.0000000000000743
  7. Hacopian AG, Brunson PB, Hall B. Patient reported outcomes and visual acuity after bilateral implantation of a next generation presbyopia correcting intraocular lens. Clin Ophthalmol. 2026;20:572703. doi:10.2147/OPTH.S572703
  8. Kang S, Arsenault SM, O'Brien RC, et al. Comparison of visual performance and patient satisfaction between two trifocal intraocular lenses: a prospective, paired eye comparative study. Clin Ophthalmol. 2026;20:572237. doi:10.2147/OPTH.S572237
  9. Hayashi K, Uno K, Hayashi S, Yoshida M. Comparison of visual performance among two multifocal extended depth of focus intraocular lens types and a trifocal intraocular lens. J Refract Surg. 2026;42(4):e327-e334. doi:10.3928/1081597X-20260212-01
  10. Pantanelli SM, O'Rourke T, Bolognia O, et al. Vision and patient reported outcomes with nondiffractive EDOF or neutral aspheric monofocal intraocular lenses. J Cataract Refract Surg. 2023;49(4):360-366. doi:10.1097/j.jcrs.0000000000001123
  11. Hovanesian JA, Jones M, Allen Q. The Vivity extended range of vision IOL versus the PanOptix trifocal, ReStor 2.5 Active Focus and ReStor 3.0 multifocal lenses: a comparison of patient satisfaction, visual disturbances, and spectacle independence. Clin Ophthalmol. 2022;16:145-152. doi:10.2147/OPTH.S347382
  12. Kohnen T, Petermann K, Bohm M, et al. Nondiffractive wavefront shaping extended depth of focus intraocular lens: visual performance and patient reported outcomes. J Cataract Refract Surg. 2022;48(2):144-150. doi:10.1097/j.jcrs.0000000000000826
  13. van Amelsfort T, Webers VSC, Bauer NJC, et al. Visual outcomes of a new nondiffractive extended depth of focus intraocular lens targeted for minimonovision: 3 month results of a prospective cohort study. J Cataract Refract Surg. 2022;48(2):151-156. doi:10.1097/j.jcrs.0000000000000825
  14. McCabe C, Berdahl J, Reiser H, et al. Clinical outcomes in a US registration study of a new EDOF intraocular lens with a nondiffractive design. J Cataract Refract Surg. 2022;48(11):1297-1304. doi:10.1097/j.jcrs.0000000000000978
  15. McNeely RN, Stewart SA, Mandal N, Moore JE. Early visual performance and subjective experience after bilateral implantation of a novel fully refractive extended depth of focus intraocular lens. Clin Ophthalmol. 2026;20:600320. doi:10.2147/OPTH.S600320
  16. Auffarth GU, Negoescu AT, Kremser F, et al. Clinical performance after implantation of a new purely refractive extended depth of field intraocular lens in cataract patients. Clin Ophthalmol. 2026;20:583059. doi:10.2147/OPTH.S583059
  17. Corbett D, Black D, Roberts TV, et al. Quality of vision clinical outcomes for a new fully refractive extended depth of focus intraocular lens. Eye (Lond). 2024;38(Suppl 1):9-14. doi:10.1038/s41433-024-03039-8
  18. Kim DY, Park ESY, Park H, et al. Comparative outcomes of the next generation extended depth of focus intraocular lens and enhanced monofocal intraocular lens in cataract surgery. J Clin Med. 2025;14(14):4967. doi:10.3390/jcm14144967
  19. Schallhorn JM, Rajanala A. Clinical outcomes of patients bilaterally implanted with the Light Adjustable Lens: results of a phase IV clinical registry. J Cataract Refract Surg. 2026. doi:10.1097/j.jcrs.0000000000001994
  20. Folden DV, Wong JR. Visual outcomes of an enhanced UV protected Light Adjustable Lens using a novel co managed, open access methodology. Clin Ophthalmol. 2022;16:2413-2420. doi:10.2147/OPTH.S378525
  21. Jun JH, Lieu A, Afshari NA. Light adjustable intraocular lenses in cataract surgery: considerations. Curr Opin Ophthalmol. 2024;35(1):44-49. doi:10.1097/ICU.0000000000001015
  22. Holladay JT, Haller M. Light adjustable lens results of spherical equivalent and astigmatism correction from the US Food and Drug Administration postapproval study. J Cataract Refract Surg. 2026;52(7):666-669. doi:10.1097/j.jcrs.0000000000001906
  23. Das KK, Werner L, Collins S, Hong X. In vitro and schematic model eye assessment of glare or positive dysphotopsia type photic phenomena: comparison of a new material IOL to other monofocal IOLs. J Cataract Refract Surg. 2019;45(2):219-227. doi:10.1016/j.jcrs.2018.09.017
  24. Muzychuk A, Harasymowycz P. Efficacy and safety evaluation of a new full visual range versus monofocal IOL in cataract patients: a randomized, controlled Canadian clinical trial. J Cataract Refract Surg. 2025. doi:10.1097/j.jcrs.0000000000001714
  25. Shultz MC, Wiley WF, Liang E, Epitropoulos AT, Whitman J. Visual and patient reported outcomes of a novel full visual range IOL versus a monofocal IOL: a randomized multicenter US trial. Am J Ophthalmol. 2025. doi:10.1016/j.ajo.2025.08.050
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.